person · Reporting owner

ROTHBLATT MARTINE A

Disclosed activity across 2 companies

Tapewire entity: 665
SEC CIK: 0001106578

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BETA Technologies, Inc.BETA · Entity 1930	Director	June 11, 2026	June 12, 2026
UNITED THERAPEUTICS CorpUTHR · Entity 664	Director · Chairperson & CEO	October 13, 2026	October 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BETA Technologies, Inc.

Report date June 11, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	8,213	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 7,142 · Balance 8,213

UNITED THERAPEUTICS Corp

Report date October 13, 2026 · Filed October 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectby Trust	333,943	Reported balance After 2026-10-13 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-10-13 · Exercise / conversion · Acquired 9,500 · Balance 333,943 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	333,304	Reported balance After 2026-10-13 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2026-10-13 · Sale · Disposed 639 · Balance 333,304 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	330,964	Reported balance After 2026-10-13 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2026-10-13 · Sale · Disposed 2,340 · Balance 330,964 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	329,472	Reported balance After 2026-10-13 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2026-10-13 · Sale · Disposed 1,492 · Balance 329,472 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	327,965	Reported balance After 2026-10-13 transaction · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · 2026-10-13 · Sale · Disposed 1,507 · Balance 327,965 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	326,513	Reported balance After 2026-10-13 transaction · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · 2026-10-13 · Sale · Disposed 1,452 · Balance 326,513 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	325,883	Reported balance After 2026-10-13 transaction · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · 2026-10-13 · Sale · Disposed 630 · Balance 325,883 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	325,185	Reported balance After 2026-10-13 transaction · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · 2026-10-13 · Sale · Disposed 698 · Balance 325,185 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	324,683	Reported balance After 2026-10-13 transaction · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · 2026-10-13 · Sale · Disposed 502 · Balance 324,683 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	324,523	Reported balance After 2026-10-13 transaction · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · 2026-10-13 · Sale · Disposed 160 · Balance 324,523 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	324,443	Reported balance After 2026-10-13 transaction · row 11 Holding and transaction disclosures are not merged. 1 source row Row 11 · 2026-10-13 · Sale · Disposed 80 · Balance 324,443 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	249,108	Reported balance Holding disclosure · report date 2026-10-13 · row 14 Holding and transaction disclosures are not merged. 1 source row Row 14 · Balance 249,108 F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Common StockSEC Table I · non-derivative	Indirectby Trust	45,596	Reported balance Holding disclosure · report date 2026-10-13 · row 15 Holding and transaction disclosures are not merged. 1 source row Row 15 · Balance 45,596 F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	8,902	Reported balance Holding disclosure · report date 2026-10-13 · row 16 Holding and transaction disclosures are not merged. 1 source row Row 16 · Balance 8,902 F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.76 · Expires 2027-03-15	Indirectby Trust	242,910	Reported balance After 2026-10-13 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-10-13 · Exercise / conversion · Disposed 9,500 · Balance 242,910 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023. F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Direct	40,513	Reported balance Holding disclosure · report date 2026-10-13 · row 12 Holding and transaction disclosures are not merged. 1 source row Row 12 · Balance 40,513
Common StockSEC Table I · non-derivative	Indirectby Spouse	166	Reported balance Holding disclosure · report date 2026-10-13 · row 13 Holding and transaction disclosures are not merged. 1 source row Row 13 · Balance 166

Filing footnotes · ownership attribution and instrument terms

F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.

F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.

F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.

F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 29, 2017 Filed Jun 30, 2017 20:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	637	$130.34	$83,027.41	Disclosure SEC source: 0001127602-17-022465 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 740 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $129.80 to $130.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 29, 2017 Filed Jun 30, 2017 20:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,237	$30.75	$38,037.75	Disclosure SEC source: 0001127602-17-022465 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
June 22, 2017 Filed Jun 23, 2017 12:26 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	943	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-022063 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,060 Underlying: Common Stock · 943 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 22, 2017 Filed Jun 23, 2017 12:26 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	1,234	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-022063 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,003 Underlying: Common Stock · 1,234 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 22, 2017 Filed Jun 23, 2017 12:26 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	943	$30.75	$28,997.25	Disclosure SEC source: 0001127602-17-022063 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 662,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 22, 2017 Filed Jun 23, 2017 12:26 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	400	$132.79	$53,117.00	Disclosure SEC source: 0001127602-17-022063 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $132.68 to $133.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 22, 2017 Filed Jun 23, 2017 12:26 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	834	$132.09	$110,165.31	Disclosure SEC source: 0001127602-17-022063 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $131.55 to $132.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 22, 2017 Filed Jun 23, 2017 12:26 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,234	$30.75	$37,945.50	Disclosure SEC source: 0001127602-17-022063 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
June 15, 2017 Filed Jun 19, 2017 12:21 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	938	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-021629 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,237 Underlying: Common Stock · 938 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 15, 2017 Filed Jun 19, 2017 12:21 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	1,238	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-021629 · form4.xml · derivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,175 Underlying: Common Stock · 1,238 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 15, 2017 Filed Jun 19, 2017 12:21 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	938	$30.75	$28,843.50	Disclosure SEC source: 0001127602-17-021629 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 661,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
June 15, 2017 Filed Jun 19, 2017 12:21 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	1,238	$130.20	$161,193.29	Disclosure SEC source: 0001127602-17-021629 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $129.82 to $130.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 15, 2017 Filed Jun 19, 2017 12:21 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,238	$30.75	$38,068.50	Disclosure SEC source: 0001127602-17-021629 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
June 08, 2017 Filed Jun 9, 2017 12:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	937	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-021007 · form4.xml · derivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,413 Underlying: Common Stock · 937 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 08, 2017 Filed Jun 9, 2017 12:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	1,240	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-021007 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,350 Underlying: Common Stock · 1,240 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 08, 2017 Filed Jun 9, 2017 12:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	100	$130.56	$13,056.00	Disclosure SEC source: 0001127602-17-021007 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 08, 2017 Filed Jun 9, 2017 12:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	740	$129.81	$96,057.92	Disclosure SEC source: 0001127602-17-021007 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $129.41 $130.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 08, 2017 Filed Jun 9, 2017 12:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	400	$128.96	$51,585.00	Disclosure SEC source: 0001127602-17-021007 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $128.37 to $129.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 08, 2017 Filed Jun 9, 2017 12:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	937	$30.75	$28,812.75	Disclosure SEC source: 0001127602-17-021007 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 660,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
June 08, 2017 Filed Jun 9, 2017 12:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,240	$30.75	$38,130.00	Disclosure SEC source: 0001127602-17-021007 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:22 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	925	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-020328 · form4.xml · derivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,590 Underlying: Common Stock · 925 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:22 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	1,251	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-020328 · form4.xml · derivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,515 Underlying: Common Stock · 1,251 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:22 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	243	$126.16	$30,655.88	Disclosure SEC source: 0001127602-17-020328 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $126.02 to $126.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:22 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	608	$125.29	$76,179.12	Disclosure SEC source: 0001127602-17-020328 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $125.02 to $125.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:22 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	300	$124.62	$37,386.99	Disclosure SEC source: 0001127602-17-020328 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $124.00 to $124.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:22 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	100	$121.83	$12,183.00	Disclosure SEC source: 0001127602-17-020328 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:22 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	925	$30.75	$28,443.75	Disclosure SEC source: 0001127602-17-020328 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 659,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:22 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,251	$30.75	$38,468.25	Disclosure SEC source: 0001127602-17-020328 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
May 25, 2017 Filed May 26, 2017 20:04 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	912	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-019558 · form4.xml · derivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,766 Underlying: Common Stock · 912 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 25, 2017 Filed May 26, 2017 20:04 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	1,265	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-019558 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,678 Underlying: Common Stock · 1,265 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 25, 2017 Filed May 26, 2017 20:04 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	100	$120.93	$12,093.00	Disclosure SEC source: 0001127602-17-019558 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 25, 2017 Filed May 26, 2017 20:04 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	300	$119.82	$35,946.00	Disclosure SEC source: 0001127602-17-019558 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $119.50 to $120.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 25, 2017 Filed May 26, 2017 20:04 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	865	$119.07	$102,999.62	Disclosure SEC source: 0001127602-17-019558 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $118.48 to $119.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 25, 2017 Filed May 26, 2017 20:04 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	912	$30.75	$28,044.00	Disclosure SEC source: 0001127602-17-019558 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 658,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
May 25, 2017 Filed May 26, 2017 20:04 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,265	$30.75	$38,898.75	Disclosure SEC source: 0001127602-17-019558 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
May 18, 2017 Filed May 22, 2017 13:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	915	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-018902 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,943 Underlying: Common Stock · 915 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 18, 2017 Filed May 22, 2017 13:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	1,261	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-018902 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,858 Underlying: Common Stock · 1,261 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 18, 2017 Filed May 22, 2017 13:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	619	$121.05	$74,927.10	Disclosure SEC source: 0001127602-17-018902 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $120.82 to $121.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 18, 2017 Filed May 22, 2017 13:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	642	$120.40	$77,298.15	Disclosure SEC source: 0001127602-17-018902 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $119.81 to $120.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 18, 2017 Filed May 22, 2017 13:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	915	$30.75	$28,136.25	Disclosure SEC source: 0001127602-17-018902 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 657,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
May 18, 2017 Filed May 22, 2017 13:27 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,261	$30.75	$38,775.75	Disclosure SEC source: 0001127602-17-018902 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
May 11, 2017 Filed May 15, 2017 13:32 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	918	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-018014 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,119 Underlying: Common Stock · 918 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 11, 2017 Filed May 15, 2017 13:32 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	1,259	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-018014 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,037 Underlying: Common Stock · 1,259 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 11, 2017 Filed May 15, 2017 13:32 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	918	$30.75	$28,228.50	Disclosure SEC source: 0001127602-17-018014 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 656,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
May 11, 2017 Filed May 15, 2017 13:32 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	312	$122.45	$38,203.18	Disclosure SEC source: 0001127602-17-018014 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $122.33 to $122.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 11, 2017 Filed May 15, 2017 13:32 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	947	$121.85	$115,396.21	Disclosure SEC source: 0001127602-17-018014 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $121.24 to $122.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 11, 2017 Filed May 15, 2017 13:32 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,259	$30.75	$38,714.25	Disclosure SEC source: 0001127602-17-018014 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document
May 04, 2017 Filed May 5, 2017 20:09 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	918	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-017065 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,296 Underlying: Common Stock · 918 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 04, 2017 Filed May 5, 2017 20:09 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	1,258	$0.00 Strike: $30.75	$0.00	Disclosure SEC source: 0001127602-17-017065 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,214 Underlying: Common Stock · 1,258 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document
May 04, 2017 Filed May 5, 2017 20:09 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	314	$122.75	$38,541.93	Disclosure SEC source: 0001127602-17-017065 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $122.58 to $123.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.